News | Artificial Intelligence | February 04, 2020

Infervision in the Frontlines Against the Coronavirus

Infervision launches the Coronavirus AI solution to help clinicians win the battle

Infervision’s deep learning medical imaging platform is helping screen patients for the coronavirus in China. It acts as second pair of eyes to identify multiple diseases from one set of chest scans. The artificial intelligence (AI) can provide a complete view of the nodule, including volume and density.

Infervision’s deep learning medical imaging platform is helping screen patients for the coronavirus in China. It acts as second pair of eyes to identify multiple diseases from one set of chest scans. The artificial intelligence (AI) can provide a complete view of the nodule, including volume and density.

February 4, 2020 — Since January 2020, the Coronavirus (2019-nCoV) outbreak at Wuhan, China, has attracted a great deal of attention from all parties in China. Everyone from Wuhan city, along with the rest of the country and world, have joined the battle to fight the Coronavirus. Working alongside, Infervision’s scientists and engineering teams have successfully launched the Coronavirus artificial intelligence (AI) solution; specially tailored for front-line use to help clinicians detect and monitor the disease efficiently and effectively.

As of Feb. 3, 2019, there were 17,205 cases of confirmed diagnosis of Coronavirus in China and 21,558 suspected cases waiting for final diagnosis. Wuhan is the epicenter, which has put an enormous amount of pressure on the local healthcare system. Find daily updates of the numbers of infected, deaths and locations from the World Health Organization website.

Infervision’s Coronavirus AI solution has been in use at the center of the epidemic outbreak at Tongji Hospital in Wuhan (Tongji Medical College of Huazhong University of Science & Technology), along with sites in other cities such as the Third People’s Hospital of Shenzhen in Shenzhen City. Infervision’s Coronavirus AI solution is accelerating pneumonia diagnosis and epidemic monitoring efforts.

The outbreak has put significant pressure on imaging departments, which are now reading over a thousand cases a day. Patients and clinicians typically have to wait a few hours to get the CT results, but Infervision AI is improving the CT diagnosis speed for each case; and each minute saved is critical to decrease the chance of cross-contamination at the hospital. The surging number of patients needing diagnosis and the strict laboratory requirements for the use of the rRT-PCR detection kit, to confirm the 2019-nCoV diagnosis, pose big challenges to regional and rural hospitals. Infervision’s tools are helping sites with limited medical resources to immediately screen out suspected Coronavirus-infected patients for further diagnosis and treatment.

While physicians are working day and night, Infervision AI is helping manage the process efficiently; assisting with pneumonia marking, abnormal and severe case analysis, patient triage, medical resources coordination, prior case comparisons and treatment assessments. The World Health Organization (WHO) has given very positive comments regarding China’s quick reaction and information transparency regarding this outbreak and voiced great confidence in China’s efforts in dealing with this public health event. The battle against this epidemic is one being fought by all clinicians and countries, and Infervision is fully committed to support these efforts, wherever needed, and aspires to “Use the most advanced technology to serve the most fundamental needs.”

For more information: www.infervision.com

 

Related Coronavirus Meical Imaging Content:

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

Infervision in the Frontlines Against the Coronavirus

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Infervision Introduces AI Capabilities for Chest CT Reading
 

Find more related clinical content Coronavirus (COVID-19)

 

 

Related Content

Videos | Artificial Intelligence | July 22, 2021
This is an overview of trends and technologies in radiology...
64-Year-Old Man With Clear Cell Likelihood Score (ccLS) 5 Renal Masses

64-Year-Old Man With Clear Cell Likelihood Score (ccLS) 5 Renal Masses. Coronal T2-weighted single shot fast spin echo and coronal T1-weighted fat-saturated spoiled gradient echo acquired during corticomedullary phase—ccLS5 lesion outlined red for clarity.

News | Magnetic Resonance Imaging (MRI) | July 22, 2021
This change will be debuted at HIMSS 2021, and Vital will be exhibiting as Canon Medical for the first time
News | Information Technology | July 22, 2021
July 22, 2021 — Canon Medical Systems Corpora
SurveyVitals, a leading patient experience analytics provider, announced it has joined forces with the Radiology Business Management Association (RBMA) to launch Postmarks, a real-time patient and partner feedback software solution
News | Patient Engagement | July 22, 2021
July 22, 2021 — SurveyVitals, a leading patient experie
An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. Viz.AI and Avicenna.AI Partner to Launch Artificial Intelligence Care Coordination for Pulmonary Embolism and Aortic Disease

An example of Viz.AI's pulmonary embolism AI application and mobile alert to the physician on-call. 

News | July 21, 2021
July 21, 2021 — Artificial int...
Registration is now open for the Radiological Society of North America (RSNA) 107th Scientific Assembly and Annual Meeting, the world’s largest annual radiology forum, to be held at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | July 21, 2021
July 21, 2021 — Registration is now open for the Radiological Society of North America (...